PF-05230907

DB18417InvestigationalProtein Based Therapies

PF-05230907 is a recombinant activated Factor X variant.

Mechanism: Pharmacologically active on Coagulation factor X
Curator reviewed
Also known as: FXA VARIANT I16L · RECOMBINANT FACTOR XA VARIANT FXAI16L
Code names: PF-05230907

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-05230907, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.